[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606112":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":37,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Instituto de Oftalmología Fundación Conde de Valenciana","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Conjunctivitis Allergic with allergen-specific immunotherapy (AIT)",null,"The study subjects will be patients with a confirmed diagnosis of allergic conjunctivitis, active symptoms, and positive skin tests, who do not present any other type of systemic or local disease or inflammatory process and who are receiving allergen-specific immunotherapy (AIT).",{"label":13,"type":10,"description":14,"interventionNames":10},"Conjunctivitis Allergic without allergen-specific immunotherapy (AIT)","The study subjects will be patients with a confirmed diagnosis of allergic conjunctivitis, active symptoms, and positive skin tests, who do not present any other type of systemic or local disease or inflammatory process, and who are not receiving immunotherapy treatment.",{"label":16,"type":10,"description":17,"interventionNames":10},"Control group","The control subjects will be clinically healthy individuals, with a normal ocular surface and no evidence of active ocular disease or local or systemic inflammatory or infectious processes.",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"María del Carmén Jiménez Martínez","CONTACT","5554421700","mcjimenezm@institutodeoftalmologia.org",[25],{"facility":26,"status":10,"city":27,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Instituto de Oftalmología FAP Conde de Valenciana, IAP Sede Centro","Mexico City","06800","Mexico","MX",{"type":32,"coordinates":33},"Point",[34,35],-99.12766,19.42847,{"lat":35,"lon":34},{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","María C. Jiménez Martínez","Head of the Immunology Department, Research Unit","100606112","treg-effector-function-and-th2treg-ratio-in-allergic-conjunctivitis-effect-of-desensitization-therapy-100606112",false,"NCT07171307","Treg Effector Function and Th2\u002FTreg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy","Study of the Effector Function of Regulatory T Cells and the Th2\u002FTreg in Patients With Allergic Conjunctivitis With and Without Desensitization Treatment","INMUNOREG","Inclusion Criteria:\n\n* Subjects aged between 5 and 30 years, of either sex.\n* Subjects with a confirmed diagnosis of allergic conjunctivitis.\n* Presence of active symptoms.\n* Positive skin tests.\n* Willingness to participate in the protocol by signing informed consent.\n\nExclusion Criteria:\n\n* Subjects who have had an infection within the two months prior to sample collection.\n* Patients with other active systemic allergic diseases (such as bronchial asthma, dermatitis, among others).\n* Subjects with chronic-degenerative or autoimmune diseases.\n* Subjects who have received topical immunosuppressive treatment in the last two months.\n* Subjects receiving systemic immunosuppressive therapy.",true,"ALL","5 Years","30 Years",{"count":54,"type":55},60,"ESTIMATED","1 Day","OBSERVATIONAL","This study aims to evaluate the effector function and expression of TIGIT and PD-1 on Tregs, as well as the Th2\u002FTreg ratio, in patients with allergic conjunctivitis with and without desensitization therapy, compared to healthy controls.\n\nPeripheral blood and tear samples will be collected once at enrollment. Treg and Th2 populations will be immunophenotyped, TIGIT and PD-1 expression assessed, and functional assays performed. Cytokine and antibody (IgE, IgG4) concentrations will be measured in serum and tears.\n\nResults will be analyzed using descriptive statistics, Shapiro-Wilk test for distribution, t-tests or ANOVA for group comparisons, and correlation analyses for associations, with p\\\u003C0.05 considered significant. This study seeks to identify immunological markers associated with disease severity and treatment response, potentially informing future therapeutic strategies.",[60],"Conjunctivitis, Allergic",[62,63,64,65],"conjunctivitis allergic","TIGIT","Tregs","PDL-1","NOT_YET_RECRUITING","2025-09-15",{"date":69,"type":70},"2025-09-17","ACTUAL",{"date":72,"type":55},"2026-01-01",{"date":74,"type":55},"2026-09",{"name":5,"class":6},1]